The GO2 Foundation together with other patient advocacy groups, has conducted a survey on the effect of COVID on lung cancer patients and recently participated in an expert panel event with Newswise.

"Now we see the pandemic kind of marching across the country and moving into smaller communities, and how do you get, not just the patients taking appropriate precautions, but those in their circle, their caregivers and their family, the health care providers?" asks Dr. Amy Moore, Director of Science and Research at GO2 Foundation. "That's I think a struggle that we find ourselves engaged in nationally. That broader dialogue of doing the right thing and looking out for your fellow man, and for cancer patients in particular. They're near and dear to us. So, we encourage everyone to just adopt those behaviours as well because you're really taking care of your fellow man," says Moore. 

Biography :
Dr. Amy Moore is the Director of Science and Research at GO2 Foundation. Dr. Amy C. Moore is a PhD-trained virologist and cancer researcher and has spent over a decade working on large statewide and multi-institution initiatives in cancer and vaccines. She currently serves as Director of Science & Research for the GO2 Foundation for Lung Cancer and also works closely with GO2 Foundation's sister organization, the Addario Lung Cancer Medical Institute (ALCMI), to build research capacity in emerging areas of concern to the lung cancer community. Because of her virology training and position as a leader in the advocacy community, Dr. Moore has become a highly sought-after expert to discuss the intersection of lung cancer and COVID-19. Since early March, she has participated in over half a dozen panel discussions, webinars, and interviews with leading groups such as IASLC, CURE, US News & World Report to discuss the threat COVID-19 presents to patients with lung cancer and how we can mobilize research to understand this risk.



“It's clear that lung cancer patients are anxious. They are fearful because what our data has shown is that lung cancer patients are uniquely vulnerable to this disease [COVID-19] and they have higher rates of severe disease and increased mortality.”